AR112541A1 - Composición para estimulación ovárica controlada con hef recombinante - Google Patents
Composición para estimulación ovárica controlada con hef recombinanteInfo
- Publication number
- AR112541A1 AR112541A1 ARP180102492A AR112541A1 AR 112541 A1 AR112541 A1 AR 112541A1 AR P180102492 A ARP180102492 A AR P180102492A AR 112541 A1 AR112541 A1 AR 112541A1
- Authority
- AR
- Argentina
- Prior art keywords
- hef
- recombinant
- composition
- ovarian stimulation
- controlled ovarian
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189119 | 2017-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112541A1 true AR112541A1 (es) | 2019-11-06 |
Family
ID=59772482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102492 AR112541A1 (es) | 2017-09-01 | 2018-08-31 | Composición para estimulación ovárica controlada con hef recombinante |
Country Status (32)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3973982T1 (sl) | 2017-09-01 | 2024-10-30 | Ferring B. V. | Sestavek za nadzorovano stimulacijo jajčnikov |
| TWI846743B (zh) | 2018-10-17 | 2024-07-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| TW202237173A (zh) * | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1250148B2 (en) * | 2000-01-27 | 2008-07-02 | Laboratoires Serono SA | Use of fsh for treating infertility |
| US20040248784A1 (en) | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| ES2494928T3 (es) * | 2007-09-21 | 2014-09-16 | Pharmabrand S.A. | Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| WO2011089602A2 (en) * | 2010-01-21 | 2011-07-28 | Ramot At Tel-Aviv University Ltd. | Aloe-emodin derivatives and use thereof for the treatment of cancer |
| US9320778B2 (en) | 2010-09-29 | 2016-04-26 | Ferring B.V. | Method for controlled ovarian stimulation with combined FSH and hCG |
| WO2012168680A1 (en) | 2011-06-06 | 2012-12-13 | Ferring B.V. | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| AR100132A1 (es) | 2014-04-18 | 2016-09-14 | Glycotope Gmbh | Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino |
| EP3261661B1 (en) | 2015-02-26 | 2023-10-18 | Ferring B.V. | Menotropin for treating infertility |
| HUE054300T2 (hu) | 2015-04-17 | 2021-08-30 | Ferring Bv | FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény |
| RS61163B1 (sr) | 2015-04-24 | 2021-01-29 | Ferring Bv | Postupak proizvodnje gonadotrofina |
| US10906953B2 (en) | 2015-06-26 | 2021-02-02 | Ferring B.V. | Methods of purification and/or viral inactivation |
| SI3973982T1 (sl) | 2017-09-01 | 2024-10-30 | Ferring B. V. | Sestavek za nadzorovano stimulacijo jajčnikov |
| WO2019211153A1 (en) | 2018-04-30 | 2019-11-07 | Ferring B.V. | Composition for controlled ovarian stimulation |
| TWI846743B (zh) | 2018-10-17 | 2024-07-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
-
2018
- 2018-08-31 SI SI201831147T patent/SI3973982T1/sl unknown
- 2018-08-31 HU HUE18768795A patent/HUE056726T2/hu unknown
- 2018-08-31 DK DK21196378.0T patent/DK3973982T3/da active
- 2018-08-31 PL PL21196378.0T patent/PL3973982T3/pl unknown
- 2018-08-31 KR KR1020207009105A patent/KR20200045543A/ko not_active Ceased
- 2018-08-31 EP EP21196378.0A patent/EP3973982B1/en active Active
- 2018-08-31 MA MA50034A patent/MA50034B1/fr unknown
- 2018-08-31 TW TW107130683A patent/TWI749255B/zh active
- 2018-08-31 EA EA202090480A patent/EA202090480A1/ru unknown
- 2018-08-31 SG SG11202003840QA patent/SG11202003840QA/en unknown
- 2018-08-31 LT LTEP21196378.0T patent/LT3973982T/lt unknown
- 2018-08-31 JP JP2020512546A patent/JP6856819B2/ja active Active
- 2018-08-31 ES ES18768795T patent/ES2904787T3/es active Active
- 2018-08-31 BR BR112020003379-0A patent/BR112020003379A2/pt unknown
- 2018-08-31 MD MDE20200700T patent/MD3675894T2/ro unknown
- 2018-08-31 CN CN201880055934.1A patent/CN111050787A/zh active Pending
- 2018-08-31 EP EP24181981.2A patent/EP4427806A3/en active Pending
- 2018-08-31 PT PT211963780T patent/PT3973982T/pt unknown
- 2018-08-31 IL IL272763A patent/IL272763B2/en unknown
- 2018-08-31 CN CN202510833422.5A patent/CN120617484A/zh active Pending
- 2018-08-31 AU AU2018326556A patent/AU2018326556B2/en active Active
- 2018-08-31 CA CA3073624A patent/CA3073624A1/en active Pending
- 2018-08-31 WO PCT/EP2018/073442 patent/WO2019043143A1/en not_active Ceased
- 2018-08-31 AR ARP180102492 patent/AR112541A1/es not_active Application Discontinuation
- 2018-08-31 UA UAA202002175A patent/UA126869C2/uk unknown
- 2018-08-31 HR HRP20241171TT patent/HRP20241171T1/hr unknown
- 2018-08-31 EP EP18768795.9A patent/EP3675894B1/en active Active
- 2018-08-31 MA MA56224A patent/MA56224B1/fr unknown
- 2018-08-31 PL PL18768795T patent/PL3675894T3/pl unknown
- 2018-08-31 ES ES21196378T patent/ES2989511T3/es active Active
- 2018-08-31 RS RS20241007A patent/RS65945B1/sr unknown
- 2018-08-31 MX MX2020002235A patent/MX2020002235A/es unknown
- 2018-08-31 SI SI201830484T patent/SI3675894T1/sl unknown
- 2018-08-31 KR KR1020257016376A patent/KR20250078595A/ko active Pending
- 2018-08-31 HU HUE21196378A patent/HUE068024T2/hu unknown
- 2018-08-31 RS RS20220042A patent/RS62810B1/sr unknown
- 2018-08-31 HR HRP20211802TT patent/HRP20211802T1/hr unknown
- 2018-08-31 MY MYPI2020000971A patent/MY200791A/en unknown
- 2018-08-31 US US16/642,777 patent/US11744879B2/en active Active
- 2018-08-31 FI FIEP21196378.0T patent/FI3973982T3/fi active
- 2018-08-31 PT PT187687959T patent/PT3675894T/pt unknown
- 2018-08-31 MD MDE20220351T patent/MD3973982T2/ro unknown
- 2018-08-31 DK DK18768795.9T patent/DK3675894T3/da active
- 2018-08-31 LT LTEPPCT/EP2018/073442T patent/LT3675894T/lt unknown
-
2020
- 2020-02-13 JO JOJO/P/2020/0034A patent/JOP20200034B1/ar active
- 2020-02-27 MX MX2024009224A patent/MX2024009224A/es unknown
- 2020-02-27 CL CL2020000482A patent/CL2020000482A1/es unknown
- 2020-02-28 PH PH12020500404A patent/PH12020500404A1/en unknown
- 2020-10-30 JP JP2020182295A patent/JP7373479B2/ja active Active
-
2023
- 2023-07-25 US US18/226,206 patent/US12653864B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
| BR112016025764A2 (pt) | vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico | |
| PE20151808A1 (es) | Peptidos terapeuticos | |
| BR112019002725A2 (pt) | uso de hidrolisado de colágeno para melhorar a capacidade de resistência e para estimular a degradação de gordura | |
| BR112016018283A2 (pt) | Composição que compreende bifidobacterium animalis ssp. lactis | |
| CL2015002691A1 (es) | Miostatina antagonista en sujetos humanos | |
| BR112017025000A2 (pt) | tratamento de hipoglicemia pós-bariátrica com exendina (9-39) | |
| CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112017019829A2 (pt) | antagonista do receptor nk-3, para o tratamento terapêutico ou cosmético de gordura corporal em excesso | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| ECSP21002804A (es) | Apirasas solubilizadas, métodos y usos | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| MX2017001632A (es) | Mioinositol y probioticos, y uso de estos. | |
| CL2020000482A1 (es) | Composición para la estimulación ovárica controlada. | |
| BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| CL2020000136A1 (es) | Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih. | |
| CL2021000928A1 (es) | Composiciones y métodos para la estimulación ovárica controlada | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
| AR107295A1 (es) | Administración intradérmica de una composición de inmunoglobulina g | |
| AR116734A1 (es) | Composiciones y métodos para estimulación ovárica controlada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |